Acquiring Company
InMed Pharmaceuticals
Acquired Company
Mentari
Description
InMed Pharmaceuticals Inc. has completed its acquisition of Mentari, enhancing its portfolio in cannabinoid-based therapies. This strategic acquisition aims to bolster InMed's capabilities in addressing rare diseases. Financial statements and further details regarding the operations of Mentari have been included in the company's filings.
Quick answer
InMed Pharmaceuticals is acquiring Mentari, announced November 16, 2026. InMed Pharmaceuticals is based in Vancouver, British Columbia, Canada.
- How much did InMed Pharmaceuticals pay for Mentari?
- The deal value was not disclosed.
- What does InMed Pharmaceuticals do?
- InMed Pharmaceuticals is a global leader in the development, manufacturing and commercialization of rare cannabinoids.
- Where are InMed Pharmaceuticals and Mentari based?
- InMed Pharmaceuticals is based in Vancouver, British Columbia, Canada.
Source: Fundz verified event record.
Other recent acquisitions in Healthcare and Biotechnology
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Vantive Enters Agreement to Divest Majority of Hemodialysis Assets to Rockwell Medical to Focus on Home Dialysis. (November 4, 2026)
- Rockwell Medical, Inc. to Acquire Vantive Limited's Hemodialysis Business (November 3, 2026)
- Pelthos to merge with Castle Creek Biosciences (October 30, 2026)
- Valo Health merges with Montai Therapeutics (November 11, 2026)
- Nuformix proposes merger with Biovara (November 11, 2026)
- Abeona Therapeutics to Acquire APT-1011 Assets from Ellodi Pharmaceuticals (November 9, 2026)
Who to call at InMed Pharmaceuticals, and when
When InMed Pharmaceuticals changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day InMed Pharmaceuticals raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at InMed Pharmaceuticals, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at InMed Pharmaceuticals. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment InMed Pharmaceuticals makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired Mentari?
Mentari was acquired by InMed Pharmaceuticals, based in Vancouver. The deal was reported on November 16, 2026. InMed Pharmaceuticals is a global leader in the development, manufacturing and commercialization of rare cannabinoids. InMed Pharmaceuticals is publicly traded (INM) and operates in Healthcare.
When did InMed Pharmaceuticals acquire Mentari?
InMed Pharmaceuticals's acquisition of Mentari was reported on November 16, 2026. InMed Pharmaceuticals Inc. has completed its acquisition of Mentari, enhancing its portfolio in cannabinoid-based therapies. This strategic acquisition aims to bolster InMed's capabilities in addressing rare diseases. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Mentari do?
Mentari is a biotechnology firm focused on advancing unique therapeutic solutions. They aim to address significant unmet medical needs through innovative biopharmaceutical development. It is privately held, operating in Biotechnology.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.